MA30866B1 - Vaccin - Google Patents

Vaccin

Info

Publication number
MA30866B1
MA30866B1 MA31843A MA31843A MA30866B1 MA 30866 B1 MA30866 B1 MA 30866B1 MA 31843 A MA31843 A MA 31843A MA 31843 A MA31843 A MA 31843A MA 30866 B1 MA30866 B1 MA 30866B1
Authority
MA
Morocco
Prior art keywords
antigen
water
oil emulsion
composition
oil
Prior art date
Application number
MA31843A
Other languages
English (en)
Inventor
William Ripley Ballou Jr
Emmanuel Jules Hanon
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0620336.8A external-priority patent/GB0620336D0/en
Priority claimed from GB0620337A external-priority patent/GB0620337D0/en
Priority claimed from GB0620816A external-priority patent/GB0620816D0/en
Priority claimed from GB0620815A external-priority patent/GB0620815D0/en
Priority claimed from PCT/EP2006/069977 external-priority patent/WO2007071710A2/fr
Priority claimed from GB0707697A external-priority patent/GB0707697D0/en
Priority claimed from GB0711357A external-priority patent/GB0711357D0/en
Priority claimed from GB0712062A external-priority patent/GB0712062D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of MA30866B1 publication Critical patent/MA30866B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UNE COMPOSITION IMMUNOGÈNE QUI CONTIENT UN ANTIGÈNE OU UNE COMPOSITION D'ANTIGÈNE ET UNE COMPOSITION D'ADJUVANT RENFERMANT UNE ÉMULSION D'HUILE DANS DE L'EAU. LADITE ÉMULSION D'HUILE DANS DE L'EAU CONTIENT 0,5 MG À 10 MG D'HUILE MÉTABOLISABLE, 0,5 MG À 11 MG DE TOCOL ET 0,1 MG À 4 MG D'AGENT ÉMULSIFIANT PAR DOSE DESTINÉE À L'HOMME.
MA31843A 2006-10-12 2009-05-06 Vaccin MA30866B1 (fr)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GBGB0620336.8A GB0620336D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620337A GB0620337D0 (en) 2006-10-12 2006-10-12 Vaccine
GB0620816A GB0620816D0 (en) 2006-10-19 2006-10-19 vaccine
GB0620815A GB0620815D0 (en) 2006-10-19 2006-10-19 Vaccine
PCT/EP2006/069977 WO2007071710A2 (fr) 2005-12-22 2006-12-20 Vaccin
PCT/EP2006/069979 WO2007071711A2 (fr) 2005-12-22 2006-12-20 Vaccin
GB0707697A GB0707697D0 (en) 2007-04-20 2007-04-20 Vaccine
GB0711357A GB0711357D0 (en) 2007-06-12 2007-06-12 Vaccine
GB0712062A GB0712062D0 (en) 2007-06-21 2007-06-21 Vaccine

Publications (1)

Publication Number Publication Date
MA30866B1 true MA30866B1 (fr) 2009-11-02

Family

ID=40551582

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31843A MA30866B1 (fr) 2006-10-12 2009-05-06 Vaccin

Country Status (18)

Country Link
US (2) US20100183667A1 (fr)
JP (2) JP5230632B2 (fr)
KR (1) KR101151202B1 (fr)
CN (1) CN101522218B (fr)
AU (1) AU2007306381B2 (fr)
BR (1) BRPI0717219B8 (fr)
CA (1) CA2664619C (fr)
CR (1) CR10726A (fr)
DK (1) DK2086582T3 (fr)
EA (1) EA015817B1 (fr)
ES (1) ES2397714T3 (fr)
HR (1) HRP20130023T1 (fr)
IL (1) IL197512A (fr)
MA (1) MA30866B1 (fr)
MX (1) MX2009003325A (fr)
NO (1) NO20091022L (fr)
PT (1) PT2086582E (fr)
WO (1) WO2008043774A1 (fr)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4812942B2 (ja) * 1999-02-26 2011-11-09 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ＣＧモチーフを含むオリゴヌクレオチドを用いるＮｅｉｓｓｅｒｉａ抗原殺菌活性の増強
DE10144906B4 (de) 2001-09-12 2013-11-28 Novartis Vaccines And Diagnostics Gmbh Verfahren zur großtechnischen Herstellung von Impfstoffen
PE20061428A1 (es) 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
JP5639760B2 (ja) 2006-07-17 2014-12-10 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム インフルエンザワクチン
ES2397714T3 (es) 2006-10-12 2013-03-08 Glaxosmithkline Biologicals S.A. Vacuna que comprende un adyuvante de emulsión de aceite en agua
BRPI0719360B1 (pt) 2006-11-03 2016-09-06 Intervet Int Bv vacina da doença de lyme canina, e, uso de organismos de uma genoespécie de borrelia
PE20090146A1 (es) 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
EP2268309B1 (fr) 2008-03-18 2015-01-21 Novartis AG Améliorations dans la préparation des antigènes pour le vaccin contre le virus de la grippe
MX2010011393A (es) * 2008-04-16 2010-11-09 Glaxosmithkline Biolog Sa Vacuna.
US20120164178A1 (en) * 2008-04-16 2012-06-28 Ballou Jr William Ripley Vaccine
RS51999B (sr) 2008-08-28 2012-04-30 Novartis Ag Dobijanje skvalena iz hiperprodukcijskih kvasaca
NZ591768A (en) 2008-09-18 2012-11-30 Novartis Ag Vaccine adjuvant combinations
ES2552383T3 (es) 2009-02-10 2015-11-27 Novartis Ag Regímenes de vacuna de la gripe para cepas asociadas a pandemias
AU2010212548A1 (en) 2009-02-10 2011-09-15 Novartis Ag Influenza vaccines with increased amounts of H3 antigen
AU2010212550B2 (en) 2009-02-10 2016-03-10 Seqirus UK Limited Influenza vaccines with reduced amounts of squalene
MX338898B (es) 2009-02-17 2016-05-03 Glaxosmithkline Biolog Sa Vacuna contra el virus del dengue inactivado con un adyuvante libre de aluminio.
US20120064103A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
EP2401384B1 (fr) 2009-05-21 2012-10-03 Novartis AG Génétique inverse utilisant des promoteurs pol i non endogènes
EP2459722B1 (fr) 2009-07-31 2017-09-06 Seqirus UK Limited Systemes de genetique inverse
GB0918392D0 (en) 2009-10-20 2009-12-02 Novartis Ag Diagnostic and therapeutic methods
WO2011048560A1 (fr) 2009-10-20 2011-04-28 Novartis Ag Procédés génétiques inverses améliorés pour le sauvetage de virus
GB0919117D0 (en) 2009-10-30 2009-12-16 Glaxosmithkline Biolog Sa Process
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
UA110103C2 (uk) 2010-01-27 2015-11-25 Ґлаксосмітклайн Байолоджікалз С.А. Модифікований туберкульозний антиген
WO2012020326A1 (fr) 2010-03-18 2012-02-16 Novartis Ag Vaccins adjuvantés contre le méningocoque de sérogroupe b
AU2011251706B2 (en) 2010-05-12 2015-10-22 Seqirus UK Limited Improved methods for preparing squalene
US8945904B2 (en) 2010-05-21 2015-02-03 Novartis Ag Influenza virus reassortment
GB201009861D0 (en) 2010-06-11 2010-07-21 Novartis Ag OMV vaccines
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
US20140248320A1 (en) 2011-10-20 2014-09-04 Novartis Ag Adjuvanted influenza b virus vaccines for pediatric priming
EP3023790A1 (fr) 2011-12-12 2016-05-25 Novartis AG Dosage pour hémagglutinines du virus de la grippe
JP2015500864A (ja) 2011-12-23 2015-01-08 ノバルティス アーゲー 黄色ブドウ球菌（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対して免疫するための安定な組成物
JP6054883B2 (ja) 2012-03-02 2016-12-27 ノバルティス アーゲー インフルエンザウイルスの再集合
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
EP2890394B1 (fr) 2012-08-31 2019-05-01 GlaxoSmithKline Biologicals SA Protéines stabilisées pour l'immunisation contre le staphylocoque doré
CN104582723A (zh) 2012-08-31 2015-04-29 诺华股份有限公司 用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
EP2892553A1 (fr) 2012-09-06 2015-07-15 Novartis AG Vaccins combinatoires avec méningococcus de sérogroupe b et d/t/p
GB201218195D0 (en) 2012-10-10 2012-11-21 Istituto Zooprofilattico Sperimentale Delle Venezie Composition
CA2886938A1 (fr) 2012-10-12 2014-04-17 Glaxosmithkline Biologicals S.A. Antigenes de pertussis acellulaires non reticules pour leur utilisation dans des vaccins combines
US9987344B2 (en) 2012-11-30 2018-06-05 Glaxosmithkline Biologicals Sa Pseudomonas antigens and antigen combinations
CA2893429A1 (fr) 2012-12-03 2014-06-12 Synthetic Genomics Vaccines, Inc. Reassortiment du virus de la grippe
HRP20230359T1 (hr) * 2012-12-05 2023-06-09 Glaxosmithkline Biologicals Sa Imunogeni pripravak
US20150320852A1 (en) 2012-12-18 2015-11-12 Glaxosmithkline Biologicals Sa Conjugates for protecting against diphtheria and/or tetanus
MX372963B (es) 2013-03-13 2020-04-01 Seqirus Uk Ltd Reordenamiento del virus de influenza b.
EP2976107B1 (fr) * 2013-03-19 2019-02-20 ASIT BioTech s.a. Préparation allergénique
SG11201509265SA (en) 2013-05-10 2015-12-30 Novartis Ag Avoiding narcolepsy risk in influenza vaccines
EP2996719B1 (fr) * 2013-05-14 2019-06-26 Zoetis Services LLC Nouvelles compositions de vaccin comprenant des oligonucléotides immunostimulateurs
DE202013005100U1 (de) 2013-06-05 2013-08-26 Novartis Ag Influenza Virus Reassortierung
DE202013005130U1 (de) 2013-06-05 2013-09-10 Novartis Ag Influenza Virus Reassortierung
CA2914604A1 (fr) 2013-06-06 2014-12-11 Novartis Ag Reassortiment du virus de la grippe
SI3096783T1 (sl) 2014-01-21 2021-09-30 Pfizer Inc. Kapsularni polisaharidi streptococcus pneumoniae in njihovi konjugati
AU2015238512B2 (en) 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
MX2016015241A (es) * 2014-05-26 2017-10-11 Becton Dickinson France Metodo para almacenar una vacuna emulsionada con adyuvante en un dispositivo de inyeccion medical lubricado.
WO2016087479A1 (fr) 2014-12-02 2016-06-09 Novartis Ag Fabrication de compositions contenant un tensioactif
WO2017005880A1 (fr) 2015-07-07 2017-01-12 Seqirus UK Limited Dosages de la puissance de la grippe
WO2017109698A1 (fr) 2015-12-22 2017-06-29 Glaxosmithkline Biologicals Sa Formulation immunogène
CN109982715A (zh) 2016-09-27 2019-07-05 免疫疫苗技术有限公司 利用低剂量体积b细胞表位组合物以在受试人中诱导抗体免疫应答的方法
CN106511996B (zh) * 2016-11-04 2019-09-10 江苏省农业科学院 用于口蹄疫疫苗的复乳型佐剂及其制备方法
US20200222550A1 (en) 2017-01-31 2020-07-16 Merck Sharp & Dohme Corp. Methods for production of capsular polysaccharide protein conjugates from streptococcus pneumoniae serotype 19f
CN109652384B (zh) * 2019-02-21 2021-10-26 昆明理工大学 一种体外培养戊型肝炎病毒的方法
IL293031A (en) 2019-11-18 2022-07-01 Seqirus Pty Ltd A method for producing reassortant influenza viruses
KR20210117832A (ko) * 2020-03-20 2021-09-29 강원대학교산학협력단 Gla-se를 포함하는 수족구병 백신 조성물
WO2022002783A1 (fr) 2020-06-29 2022-01-06 Glaxosmithkline Biologicals Sa Adjuvants
MX2023002356A (es) 2020-08-24 2023-03-22 Sanofi Pasteur Inc Vacunas contra la covid-19 con coadyuvantes en emulsion de escualeno que contiene tocoferol.
US20240165224A1 (en) 2021-03-26 2024-05-23 Glaxosmithkline Biologicals Sa Immunogenic compositions
WO2023020993A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020992A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
WO2023020994A1 (fr) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Nouveaux procédés
KR102901149B1 (ko) * 2022-09-05 2025-12-17 주식회사 차백신연구소 에멀전 제형의 면역증강제 조성물 및 이의 제조 방법
CN120346163A (zh) * 2024-01-22 2025-07-22 中国科学院过程工程研究所 水包油乳液

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2905287A1 (de) 1979-02-12 1980-08-21 Siemens Ag Verfahren zur automatischen elektrochemischen endpunktsbestimmung einer titration
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4454119A (en) 1981-06-29 1984-06-12 Mitsubishi Chemical Industries Limited Therapeutic agents
FI69639C (fi) * 1982-07-02 1986-03-10 Orion Yhtymae Oy Preparat foer anvaendning vid klamydia-diagnostik
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
WO1988009797A1 (fr) 1987-06-05 1988-12-15 The United States Of America, As Represented By Th Facteurs de motilite de l'autocrine dans le diagnostic et le traitement du cancer
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
EP0304578B1 (fr) 1987-06-22 2001-10-24 Medeva Holdings Bv Peptide contenant l'antigène de surface de l'hépatite B
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
GB8819209D0 (en) 1988-08-12 1988-09-14 Research Corp Ltd Polypeptide & dna encoding same
US4999403A (en) 1988-10-28 1991-03-12 Exxon Chemical Patents Inc. Graft polymers of functionalized ethylene-alpha-olefin copolymer with polypropylene, methods of preparation, and use in polypropylene compositions
MC2178A1 (fr) 1988-12-16 1992-05-22 Nederlanden Staat Mutants de la pneumolysine et vaccins a base de pneumocoque prepares a partir de ces mutants
DE69015222T2 (de) 1989-02-04 1995-05-04 Akzo Nv Tocole als Impfstoffadjuvans.
WO1990014837A1 (fr) * 1989-05-25 1990-12-13 Chiron Corporation Composition d'adjuvant comprenant une emulsion de gouttelettes d'huile d'une taille inferieure au micron
EP0414374B1 (fr) 1989-07-25 1997-10-08 Smithkline Biologicals S.A. Antigènes ainsi que les méthodes pour leur préparation
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
CA2123612C (fr) 1991-11-16 2002-06-25 Michel De Wilde Proteine hybride entre la proteine cs de plasmodium et l'antigene de surface du virus de l'hepatite b
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
SG48309A1 (en) 1993-03-23 1998-04-17 Smithkline Beecham Biolog Vaccine compositions containing 3-0 deacylated monophosphoryl lipid a
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995024176A1 (fr) 1994-03-07 1995-09-14 Bioject, Inc. Dispositif de remplissage d'ampoule
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
WO1995026204A1 (fr) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Stimulation immunitaire par des analogues d'oligonucleotides de phosphorothioate
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
WO1996026277A1 (fr) 1995-02-24 1996-08-29 Cantab Pharmaceuticals Research Limited Polypeptides utiles comme agents immunotherapeutiques et procedes de preparation de polypeptides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US7184826B2 (en) 1996-06-18 2007-02-27 Alza Corporation Device and method for enhancing transdermal flux of agents being delivered or sampled
US20030133944A1 (en) * 2001-04-05 2003-07-17 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
AU722574B2 (en) 1996-12-20 2000-08-10 Alza Corporation Device and method for enhancing transdermal agent flux
US6130043A (en) 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
AU740956B2 (en) 1997-07-21 2001-11-15 Baxter Healthcare Sa Modified immunogenic pneumolysin compositions as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
US7459524B1 (en) 1997-10-02 2008-12-02 Emergent Product Development Gaithersburg Inc. Chlamydia protein, sequence and uses thereof
EP2218732A1 (fr) 1997-11-28 2010-08-18 Merck Serono Biodevelopment Séquence génomique de Chlamydia pneumoniae, polypeptides, fragments et leurs utilisations, en particulier pour le diagnostic, la prévention et le traitement de l'infection
CN1285753A (zh) 1997-12-02 2001-02-28 鲍德杰克特疫苗公司 透皮给药微粒疫苗组合物
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
KR100797876B1 (ko) 1998-04-07 2008-01-24 코릭사 코포레이션 마이코박테리움 튜베르쿨로시스 항원의 융합 단백질 및이의 용도
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
GB9923176D0 (en) * 1999-09-30 1999-12-01 Smithkline Beecham Biolog Novel composition
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
JP2001316251A (ja) * 2000-02-24 2001-11-13 Fuairudo Kk 炭素燃焼残査の超微粒子を含むスクワラン及びその製造方法
GB0025577D0 (en) * 2000-10-18 2000-12-06 Smithkline Beecham Biolog Vaccine
DE60230340D1 (de) 2001-11-16 2009-01-22 3M Innovative Properties Co N-Ä4-(4-Amino-2-ethyl-1H-imidazoÄ4,5-cÜchinolin-1-yl)butylÜmethanesulfonamide, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung
PE20061428A1 (es) * 2005-03-23 2007-01-16 Glaxosmithkline Biolog Sa Formulacion de vacuna que comprende un adyuvante de emulsion aceite en agua y 3d-mpl
WO2007052155A2 (fr) * 2005-11-04 2007-05-10 Novartis Vaccines And Diagnostics Srl Vaccins antigrippaux presentant un taux reduit d'adjuvants de type emulsion
ES2397714T3 (es) * 2006-10-12 2013-03-08 Glaxosmithkline Biologicals S.A. Vacuna que comprende un adyuvante de emulsión de aceite en agua
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza

Also Published As

Publication number Publication date
KR20090066323A (ko) 2009-06-23
CA2664619A1 (fr) 2008-04-17
JP2013067646A (ja) 2013-04-18
BRPI0717219B8 (pt) 2021-05-25
WO2008043774A1 (fr) 2008-04-17
BRPI0717219B1 (pt) 2021-01-19
CN101522218A (zh) 2009-09-02
CN101522218B (zh) 2012-09-26
US20150359863A1 (en) 2015-12-17
JP5230632B2 (ja) 2013-07-10
DK2086582T3 (da) 2013-02-04
US20100183667A1 (en) 2010-07-22
CA2664619C (fr) 2012-12-11
KR101151202B1 (ko) 2012-06-11
NO20091022L (no) 2009-04-27
ES2397714T3 (es) 2013-03-08
IL197512A (en) 2013-10-31
MX2009003325A (es) 2009-04-09
CR10726A (es) 2009-05-25
HRP20130023T1 (hr) 2013-02-28
BRPI0717219A2 (pt) 2015-05-26
JP2010505907A (ja) 2010-02-25
US9700605B2 (en) 2017-07-11
EA015817B1 (ru) 2011-12-30
PT2086582E (pt) 2013-01-25
EA200900350A1 (ru) 2009-10-30
IL197512A0 (en) 2011-08-01
AU2007306381A1 (en) 2008-04-17
JP5767201B2 (ja) 2015-08-19
AU2007306381B2 (en) 2011-12-08

Similar Documents

Publication Publication Date Title
EA200900350A1 (ru) Вакцина, содержащая адъювант в виде эмульсии "масло в воде"
MA30624B1 (fr) Vaccin anti-grippal
MA29715B1 (fr) Utilisation d'un virus de la grippe et d'un adjuvant de type emulsion huile dans l'eau pour induire une cellule t cd-4 et/ou ameliorer la reponse de la cellule a memoire b
MA31381B1 (fr) Vaccin contre la grippe a emulsion huile dans l'eau
MA29714B1 (fr) Vaccin
CY1116904T1 (el) Εμβολιο
MA30023B1 (fr) Nouvelle composition
WO2006037089A3 (fr) Compositions faiblement huileuses pour la liberation de taxoides et d'autres medicaments insolubles
AR047841A1 (es) Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
UA94404C2 (ru) Новые композиции вакцин
EA201690265A3 (ru) Фармацевтические композиции, содержащие замещенные ациланилиды
CL2007001698A1 (es) Composicion inmunogenica que comprende los lipooligosacaridos meningococicos (los) de inmunotipos l2 y l3 de cepas neissericas; composicion de vacuna que la comprende; procedimiento de preparacion; y su uso para la prevencion o tratamiento de enfermedades causadas por uno o mas serogrupos de n. meningitidis.
BRPI0516718B8 (pt) formulação de liberação modificada de ibuprofeno fornecendo liberação imediata e prolongada do fármaco
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
SG164369A1 (en) Human anti-b7rp1 neutralizing antibodies
TW200801042A (en) Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
MA29459B1 (fr) Vaccins
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
BRPI0418330A (pt) composições sólidas de drogas de solubilidade baixa e poloxámeros
EA201001478A1 (ru) Вакцина
MA30691B1 (fr) Compositions pharmaceutiques contenant un anticorps monoclonal anti-idiotypique anti-ca-125 et de l'aluminium.
MA27925A1 (fr) Combinaisons d'un inhibiteur de cathepsine k et d'un bisphophonate utilisees dans le traitement des metastases osseuses, de la croissance des tumeurs et de la perte osseuse induite par une tumeur
BRPI0414073A (pt) método para induzir uma resposta imune contra infecção por rotavìrus a partir de um sorotipo de rotavìrus, e, uso de uma cepa de rotavìrus atenuado de um sorotipo
CY1113746T1 (el) Εμβολιο που περιλαμβανει ανοσοενισχυτικο γαλακτωμα ελαιου σε υδωρ
PT1250125E (pt) Composicoes farmaceuticas contendo terbinafina